Core Insights - Foghorn Therapeutics is advancing its clinical-stage programs, particularly focusing on FHD-909 for SMARCA4-mutant cancers, with a strong emphasis on non-small cell lung cancer (NSCLC) [1][3] - The company has successfully completed a $50 million registered direct financing, enhancing its financial position and extending its cash runway into the first half of 2028 [2][4] Financial Overview - As of December 31, 2025, Foghorn had cash, cash equivalents, and marketable securities totaling $158.9 million, which supports operations until mid-2028 [2][19] - Collaboration revenues increased to $30.9 million for the year ended December 31, 2025, up from $22.6 million in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [19] - Research and development expenses decreased to $85.5 million in 2025 from $94.5 million in 2024, primarily due to reduced costs in FHD-286 and other operational efficiencies [19] Clinical Development - FHD-909 is a first-in-class oral SMARCA2 selective inhibitor, currently in a Phase 1 trial targeting NSCLC patients with SMARCA4 mutations, where treatment outcomes are typically poor [6][15] - The trial is progressing well, with the first patient dosed in October 2024, and preclinical data suggests enhanced anti-tumor activity when combined with pembrolizumab and KRAS inhibitors [6][7] - The Selective CBP and EP300 degrader programs are on track for IND-enabling studies in 2026, targeting various cancers including ER+ breast cancer and multiple myeloma [1][8][9] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program, which includes both a selective inhibitor and a selective degrader [7] - The collaboration also encompasses three discovery programs from Foghorn's Gene Traffic Control platform, indicating a robust partnership aimed at developing novel oncology treatments [7] Leadership Changes - In February 2026, Foghorn appointed Ryan Maynard as Chief Financial Officer, bringing over 25 years of experience in financial strategy and capital markets execution within the biopharmaceutical sector [5]

Core Insights - Foghorn Therapeutics is advancing its pipeline, particularly focusing on FHD-909, a first-in-class oral SMARCA2 selective inhibitor, which is currently in a Phase 1 dose escalation trial targeting non-small cell lung cancer (NSCLC) [1][3][4] - The company has shown promising preclinical data indicating synergistic effects of FHD-909 when combined with pembrolizumab and KRAS inhibitors, suggesting significant potential in treating difficult-to-treat NSCLC [2][4] - Foghorn's selective degrader programs targeting CBP, EP300, and ARID1B are progressing well, with updates expected in Q4 2025 and an IND application for the Selective CBP degrader anticipated in 2026 [2][6][12] Financial Overview - As of June 30, 2025, Foghorn reported cash, cash equivalents, and marketable securities totaling $198.7 million, providing a cash runway into 2028 [1][18] - Collaboration revenue for the three months ended June 30, 2025, was $7.6 million, an increase from $6.9 million in the same period in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [10][21] - The net loss for the three months ended June 30, 2025, was $17.9 million, compared to a net loss of $23.0 million for the same period in 2024, indicating improved financial performance [18][21] Pipeline and Development Programs - FHD-909 is designed to selectively inhibit SMARCA2, which is crucial for the survival of tumors with SMARCA4 mutations, and has shown significant anti-tumor activity in preclinical models [3][13] - The Selective CBP degrader program targets EP300-mutated cancer cells and has shown encouraging activity in ER+ breast cancer, with potential applications beyond EP300-mutant tumors [2][6][11] - The Selective EP300 degrader is being developed for hematological malignancies and prostate cancer, with updates expected in Q4 2025 [7][11] - The Selective ARID1B degrader targets ARID1B in ARID1A-mutated cancers, which are prevalent in various solid tumors, and has achieved selective degradation in preclinical studies [8][12] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for FHD-909, which is currently enrolling patients in a Phase 1 trial [4][5] - The collaboration aims to develop novel oncology medicines, leveraging both companies' strengths in drug development [4][5]